Prostate News and Research

RSS

GENova Biotherapeutics discusses its anti-cancer drug development strategy

GENova Biotherapeutics, Inc., ("GENova"), today released important information about its anti-cancer drug development strategy and its unique niche in the drug development industry.

9 Sep 2009

TURis plasma vaporization electrode for benign prostatic hyperplasia therapy

The TURis plasma vaporization electrode does not cut off tissue with a loop, but energetically vaporizes the tissue with a small button electrode. With the help of the latest plasma technology, cells can be removed by merely gliding the electrode over the prostate tissue.

From Evident Corporation - Life Sciences 9 Sep 2009

Prostate cancer treatment options discussed in a study

A new study in the Journal of the American Medical Association (JAMA) appears to support the theory outlined in earlier studies that men with more advanced forms of prostate cancer don't benefit from a combination of hormone and radiation therapy.

9 Sep 2009

GENova Biotherapeutics files patent for Prostaganin anti-cancer drug

GENova Biotherapeutics, Inc., ("GENova"), is pleased to announce that it has filed a patent for a novel peptide that disrupts the advance of prostate cancer and thus has blockbuster potential as a new anti-cancer drug.

9 Sep 2009

Research study highlights unique aspects of tumor immunology

Immune responses are capable of killing tumors before they can be directed toward normal body tissue, according to new scientific findings published in Cancer Research, a journal of the American Association for Cancer Research.

9 Sep 2009

Patient enrollment for Phase 2b study of PRX302 completed by Protox Therapeutics

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced that it has completed patient enrollment in its multi-centre, double-blinded, placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in males with moderate to severe benign prostatic hyperplasia (BPH), a common and bothersome urological condition that affects more than 50 million men worldwide.

8 Sep 2009

Active cannabis chemicals halt prostate cancer cell growth

ACTIVE chemicals in cannabis have been shown to halt prostate cancer cell growth according to research published in the British Journal of Cancer today.

8 Sep 2009

Presence of virus linked with malignant human prostate cancer cells

In a finding with potentially major implications for identifying a viral cause of prostate cancer, researchers at the University of Utah and Columbia University medical schools have reported that a type of virus known to cause leukemia and sarcomas in animals has been found for the first time in malignant human prostate cancer cells.

7 Sep 2009

Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice

Nanoparticle delivery of diphtheria toxin-encoding DNA that expresses selectively in ovarian cancer cells reduced the burden of ovarian tumors in mice, and researchers expect that this therapy could be tested in humans with advanced ovarian cancer within 18 to 24 months, according to a report in Cancer Research. If additional tests are successful, these finding could lead to a new treatment for ovarian cancer, which now causes more than 15,000 deaths each year in the United States. Because it is usually diagnosed at a relatively late stage, ovarian cancer is one of the most deadly forms of the disease.

7 Sep 2009

Two new da Vinci Si HD Surgical System robots added to Swedish Medical Center

As one of the first medical centers in the Northwest to perform robot-assisted surgery, Swedish Medical Center is home to the fastest-growing and most experienced robot-assisted surgical program in the region. Swedish established the multidisciplinary robot-assisted surgical program in 2005 and has since performed more than 2,000 robot-assisted surgeries, more than any other program in the region.

4 Sep 2009

Periurethral suspension technique results in greater continence rates after RALIP

The September issue of European Urology, the official journal of the European Association of Urology, features an article and a video in the Surgery in Motion section by Vipul R. Patel et al, showing that the periurethral suspension technique results in significantly greater continence rates at 3 months after robot-assisted laparoscopic radical prostatectomy (RALP).

4 Sep 2009

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

A key compound resupplies bone marrow with fast-acting stem cells that can more quickly rekindle blood cell production, according to a study published online today in the journal Blood. While the study was in mice, in the study authors say it has the potential to increase survival among patients with life-threatening blood cell shortages.

3 Sep 2009

Algeta partners with Bayer for development and commercialization of Alpharadin drug

Algeta Retains Option for Co-promotion and Profit Sharing in USA - Potential deal value of $800 million (EUR560m*) plus tiered double digit royalties - Algeta to receive $61 million (EUR42.5m) cash upfront, followed by development and sales milestones - Algeta retains option for co-promotion and profit-sharing in USA - Algeta and Bayer will jointly develop Alpharadin, with Bayer contributing a substantial majority of the costs of future development

3 Sep 2009

IGRT offers improved treatment results for obese prostate cancer patients

Moderately to severely obese prostate cancer patients may have improved treatment outcomes when treated with image-guided radiation therapy (IGRT) over traditional external beam radiation therapy (EBRT) because IGRT corrects for prostate shifts, which, if not planned for, can lead to incorrect doses of radiation to the disease site, according to a study in the September 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

3 Sep 2009

Alloantigen-specific Treg cells targeted for organ transplantation

An increased understanding of the role of the body's immune system in the development of diseases such as prostate cancer, squamous cell carcinoma (a type of skin cancer), type 1 diabetes, autoimmune liver disease, and in the rejection of transplanted organs by some transplant patients, has paved the way for a pioneering research programme which aims to develop 'enhanced' cells as therapies.

3 Sep 2009

NCI to announce the results of follow-up study of PharmaGap's lead drug GAP-107B8

PharmaGap Inc. (TSX-V: GAP; OTC.BB: PHRGF) ("PharmaGap" or "the Company") today announced that results are expected during September from the United States National Cancer Institute (NCI) follow-up study of the company's lead drug GAP-107B8.

2 Sep 2009

Dr. Samadi of the Mount Sinai Medical Center stresses on prostate cancer awareness

September signifies the start of fall, back to school and back to homework. September is also National Prostate Cancer Awareness Month. The awareness month was proclaimed by President Bush in 2003, and bolstered later that year by former New York mayor Rudy Giuliani, a prostate cancer survivor, who became the spokesman for the National Prostate Cancer Coalition.

2 Sep 2009

St. Luke's Episcopal Hospital uses CyberKnife robotic radiosurgery system for treating tumours

St. Luke's Episcopal Hospital is the first hospital in Houston to feature the CyberKnife((R)), a noninvasive alternative to surgery for the treatment of both cancerous and non-cancerous tumors.

2 Sep 2009

TRAF6 protein plays a role in cell growth and carcinogenesis, says researchers

The mainstay immune system protein TRAF6 plays an unexpected, key role activating a cell signaling molecule that in mutant form is associated with cancer growth, researchers at The University of Texas M. D. Anderson Cancer Center report in the Aug. 28 edition of Science.

2 Sep 2009

New findings on molecular imaging and prostate cancer

A new study published in the September issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET)/computer tomography (CT) scans with the imaging agent choline could detect recurring prostate cancer sooner than conventional imaging technologies in some patients who have had their prostates surgically removed.

2 Sep 2009

Prostate News and Research

GENova Biotherapeutics discusses its anti-cancer drug development strategy

TURis plasma vaporization electrode for benign prostatic hyperplasia therapy

Prostate cancer treatment options discussed in a study

GENova Biotherapeutics files patent for Prostaganin anti-cancer drug

Research study highlights unique aspects of tumor immunology

Patient enrollment for Phase 2b study of PRX302 completed by Protox Therapeutics

Active cannabis chemicals halt prostate cancer cell growth

Presence of virus linked with malignant human prostate cancer cells

Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice

Two new da Vinci Si HD Surgical System robots added to Swedish Medical Center

Periurethral suspension technique results in greater continence rates after RALIP

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

Algeta partners with Bayer for development and commercialization of Alpharadin drug

IGRT offers improved treatment results for obese prostate cancer patients

Alloantigen-specific Treg cells targeted for organ transplantation

NCI to announce the results of follow-up study of PharmaGap's lead drug GAP-107B8

Dr. Samadi of the Mount Sinai Medical Center stresses on prostate cancer awareness

St. Luke's Episcopal Hospital uses CyberKnife robotic radiosurgery system for treating tumours

TRAF6 protein plays a role in cell growth and carcinogenesis, says researchers

New findings on molecular imaging and prostate cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News